All posts
-
Eramet shares slump as financial and governance crisis deepens at miner
French team reveals prepare for possession sales and resources elevate weeks after shooting of chief executive officer
-
Vertical Aerospace To Bring its Valo eVTOL Aircraft to Miami Next Month and Shares Example Routes in Region
Upright Aerospace will certainly bring its next-generation electrical airplane Valo to Miami, where it will certainly get on show and tell from February 24th to 25th. The city is t…
-
Novo Nordisk to face rising threat from generic competitors
Novo Nordisk’s license on semaglutide is readied to end in March throughout numerous markets.
-
Novo Nordisk CMO on high-dose Wegovy: More patients reach goals
New EU authorization of Wegovy in high-dose kind will certainly bring about higher weight-loss for individuals.
-
Genmab drops diversity targets for senior management
The pharmaceutical firm did not accomplish its sex variety targets for 2025 and is currently dropping them for elderly monitoring, while preserving a target for monitoring listed b…
-
Eli Lilly reports improved outcomes in overweight psoriasis patients with combination therapy
After 36 weeks, clients attained clear skin and considerable weight reduction with mix treatment.
-
Leo Pharma hit by headwinds in China: “We haven’t launched anything in more than a decade”
Leo Pharma will certainly once more get along with brand-new launches in China after encountering headwinds in 2025. The chief executive officer has high assumptions for 2 items sp…
-
Genmab posts strong revenue growth, earnings below analysts’ expectations
Genmab’s complete income raised to USD 3,720 m from USD 3,121 m.
-
Genmab faces “decisive year” in 2026 with key trial results on the horizon
According to Genmab’s chief executive officer, as much as 6 medical tests in 2026 can be crucial for prospective brand-new launches of prospective smash hits in 2027.
-
Genmab received USD 12.5m in payment from Novo Nordisk in 2025
Genmab’s milestone payments from its partners totaled USD 97m in 2025.
